- Home
- VGI vs RVPH Comparison
VGI vs RVPH Comparison
Compare VGI & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VGI | RVPH |
|---|---|---|
| Founded | 2012 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.4M | 71.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | VGI | RVPH |
|---|---|---|
| Price | $7.89 | $0.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $3.14 |
| AVG Volume (30 Days) | 46.0K | ★ 8.6M |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 12.66% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.68 | $0.25 |
| 52 Week High | $7.99 | $2.17 |
Technical Indicators
Market Signals| Indicator | VGI | RVPH |
|---|---|---|
| Relative Strength Index (RSI) | 61.60 | 35.22 |
| Support Level | $7.82 | $0.27 |
| Resistance Level | $7.94 | $0.34 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 83.72 | 17.76 |
Price Performance
Historical ComparisonAbout VGI Virtus Global Multi-Sector Income Fund of Beneficial Interest
Virtus Global Multi-Sector Inc is a United States based fund. Its investment objective is to maximize current income while preserving capital. The Fund seeks to achieve its investment objective by applying extensive credit research to capitalize on opportunities across undervalued areas of the international bond markets.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.